Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
Acquisition expands high-value medical platform
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Subscribe To Our Newsletter & Stay Updated